.Attributes Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint requires inclusion of patients along with MASLD as well as size of liver end results in cardio-- renal-- metabolic tests, when data recommend mechanistically tenable benefits as well as professional safety and security-- and details considerations for trial concept and regulative approval.